Callouts & quotes from 37,061+ activist slides

"Exiting Thermal Coal Producers - Thermal coal is significantly carbon intensive, becoming less and less economically viable, and highly exposed to regulation because of its environmental impacts. With the acceleration of the global energy transition, we do not believe that the long-term economic or investment rationale justifies continued investment in this sector. As a result, we are in the process of removing from our discretionary active investment portfolios the public securities (both debt and equity) of companies that generate more than 25% of their revenues from thermal coal production, which we aim to accomplish by the middle of 2020 — BlackRock, Sustainability as BlackRock's New Standard for Investing, 2020 Letter to Clients"

""While GSE revenues and earnings are significantly higher now vs pre-GFC levels driven by much higher guarantee fees and meaningfully larger guarantee portfolios, required minimum capital levels have increased far more meaningfully, resulting in a sharp decline in run-rate ROEs. We believe that the only realistic way to solve for this is to remove the stability buffer and take the minimum capital level back to 2.5%. The other alternative is to increase guarantee fees, but we estimate that the increases would have to be in the 20-25 bp range (from the current 65 bp level), which is likely to be politically unacceptable since it would increase mortgage rates by an equivalent amount." — Keefe, Bruyette & Woods (emphasis added), 1/5/2025"

""The Company's catastrophe reinsurance treaty allows for the combining of events that occur within a 150-mile radius as a single occurrence" — MCY PR. "The hours clause and the radius clause are the key term that are going to be in everybody's [treaty]. So they cite those. The whole PCS thing, honestly, I think there's some bluster there, that they're [MCY] are just posturing." — Reinsurance expert. "Additionally, if each individual event is classified as its own catastrophic event by the Property Claims Service ("PCS"), a unit of the Insurance Services Office, each event can be considered a separate occurrence. In the case of the Palisades and Eaton wildfires, the PCS has designated each as a separate event." — MCY contract excerpt."

""Investors want to hear one thing... You’re not going to be able to run a calculation that’s worth anything. I think something that’s not talked about with honesty is how big of a challenge that is and how much room needs to be covered to get to a point where even if we have dozens of qubits, they’re not actually able to do anything useful." — Former IonQ employee, physicist; "There is definitely quantum hype right now, definitely, without a doubt... the small 10-qubit devices are mainly toys right now. That’s the fact of the matter... Everything that’s available right now is only useful for researchers who want to test that the scripts that they are writing can run in the toy examples." — Ex-IonQ employee, member of technical staff"

"“Because remote cardiac monitoring technology, including the Zio System, is rapidly evolving, there is a continuing risk that relative value units assigned, and reimbursement rates set, by CMS may not adequately reflect the value and expense of this technology and associated monitoring services, and CMS may reduce these rates in the future, which would adversely affect the Company's financial results.” — iRhythm 2024 10-K. “[the] MCT category is going to be slightly flat over time. I think that there continues to be a nice healthy market there, but we know that price has been under a bit of pressure from CMS for the last 2 years. I suspect that will continue to be the case...” — iRhythm CEO Blackford on Q1 2025 Earnings Call, 5/1/25"

""As at 31 December 2019, the Company had an overdue debt towards the banks BNP Paribas SA, Banca IFIS SpA, Unione di Banche Italiane SpA, AMCO – Asset Management Company SpA, Banca Monte dei Paschi di Siena SpA and Banca Carige SpA for an amount equal to Euro 22,196. On 29 December 2020, this debt, within the broader process of acquiring the shares of the Companies by the CPI group, was purchased without recourse by CPI Italy 130 SPV Srl, a vehicle controlled by the parent company CPI PG, and, therefore, it was reclassified among “Payables to companies subject to the control of the parent companies.” The formalization of the debt renegotiation beyond the 2022 financial year is underway." — Millennium S.r.l. Financial Statements 2021"

"They're not using the treadmill right now because it's a clothes hanger and it's dusty. Nobody likes running on a treadmill at home because it's boring... We can bring our insanely motivating fantastic instructors into your home, onto your 60-inch television screen... And with that subscription, they get yoga included. They get out to running included. They get cycling. They can go to their gym... We believe it's five years from now, two years from now, when your treadmill breaks, you're going to go to a Peloton store near you and you're going to see one of our two treadmills and you say honey, I don't want the dopey old treadmill from the dopey old fitness equipment company of yesteryear. I want it Peloton tread. — John Foley (CEO)"

""if you got somebody on diazoxide and you've got somebody on growth hormone... that also is increasing your risk of diabetes...in DKA in overweight people, you also can get type 2 diabetes and wind up in a different type of ketoacidosis with hyperosmolar problems and coma...we've had a couple of deaths from DKA, but we've actually had two from hyperosmolar, type 2's...you're on a second medication that is increasing your sugar while you're on a medication that may be decreasing your insulin...and if you get DKA in type 2, there's a subset that gets something called hyperosmolar...it's bad and very, very difficult to treat...it has a relatively high mortality rate...." — Pediatric endocrinologist, division chief at an academic center"

""if you got somebody on diazoxide and you've got somebody on growth hormone... that also is increasing your risk of diabetes...in DKA in overweight people, you also can get type 2 diabetes and wind up in a different type of ketoacidosis with hyperosmolar problems and coma...we've had a couple of deaths from DKA, but we've actually had two from hyperosmolar, type 2's...you're on a second medication that is increasing your sugar while you're on a medication that may be decreasing your insulin...and if you get DKA in type 2, there's a subset that gets something called hyperosmolar...it's bad and very, very difficult to treat...it has a relatively high mortality rate...." — Pediatric endocrinologist, division chief at an academic center"

""it's a very big concern...bananas...you're blocking insulin production in kids who are prone to obesity and diabetes." — Pediatric endocrinologist, division chief at an academic center; "Yeah, certainly I'm aware of it. Actually, one of the last kids who I treated for hyperinsulinism, who had big-time insulin doses, i was fairly aggressive, and I put the kid into mild failure." — Pediatric endocrinologist, division chief at an academic center; "I was unaware that there are different channelopathies that develop based on your Prader-Willi mutation...But if that's true, and nephrologists are much smarter than endocrinologists, that would certainly increase my concern." — Pediatric endocrinologist, division chief at an academic center"

""Walk into a quantum lab where scientists trap ions, and you'll find benchtops full of mirrors and lenses, all focusing lasers to hit an ion “trapped” in place above a chip. By using lasers to control ions, scientists have learned to harness ions as quantum bits, or qubits, the basic unit of data in a quantum computer. But this laser setup is holding research back — making it difficult to experiment with more than a few ions and to take these systems out of the lab for real use." — MIT article, https://news.mit.edu/2020/lighting-ion-trap-1104; "However, current implementations rely on free-space optics for ion control, which limits their portability and scalability." — Nature paper, https://www.nature.com/articles/s41586-020-2811-x"

""We believe the question of whether Kao accelerates growth for beauty care and cosmetics in FY2025 is very important for achieving FY2025 guidance and the medium-term business plan" — J.P. Morgan. "The health & beauty care business did not perform as well as we were expecting, due partly to the booking of costs associated with business revamps and higher marketing outlays. The cosmetics business also continued to struggle." — Daiwa. "Growth strategies for health & beauty care and cosmetics look a bit underwhelming based on 4Q results and FY12/25 sales guidance" — SMBC. "[Hasebe] noted that cosmetics are a high-margin business and that the company would work towards a 15-20% OPM in the business without providing a timeframe" — CLSA."

""So let me conclude. Lots going on. We are creating a sustainable value for our shareholder. We continue to deliver strong operational results, profitable growth, driven organic as well as inorganic, fully on track, disciplined execution...." — Dr. Klaus Kleinfeld, April 8, 2015; "This is very much in line and on track to achieve the targets that we set out in our 3-year targets, our 2016 targets." — Dr. Klaus Kleinfeld, January, 12, 2015; "Global Rolled Products, Transportation and Construction Solutions are on track to meet their three-year targets" — Dr. Klaus Kleinfeld, April 11, 2016; "So, that’s pretty much what’s been happening, strong operational results, transformation fully on track." — Dr. Klaus Kleinfeld, April 8, 2015"

"The demand for prospective participants thus increased in geometric progression while the number of potential investors available in a given community or geographical area remained relatively constant. . . . The exhaustion of prospects results from over-saturation . . . [T]he imposition of an inappropriate statewide quota did not negate the endless chain representation, nor did it prevent the chain from soon reaching the saturation point in a number of local areas. This was largely because, with rare exceptions, distributors naturally tended to recruit in their own circumscribed local areas, and the chain soon ended in such an area before a statewide quota was breached. — 86 F.T.C. 1114, 1132-33 (In re Koscot Interplanetary, Inc.)"

"Investor: So does Eurofins participate in factoring of AR or reverse factoring of AP? Eurofins: We didn't, we do not do factoring. We never did factoring. There's, uh—we don't see reasons for doing that. Investor: Okay, so there's no factoring, either AR or AP? Eurofins: Nothing. Just, no, no... Anyway, it would have to be disclosed. If you, if you lend your receivables to a bank that will then be disclosed in the borrowing side. Investor: Right, right. Especially if they are recourse. So why did [a disclosure that Eurofins does not factor] get removed [beginning in 2021]? Eurofins: I don't know. I don't know...We didn't do that, never been an option for us. — Transcript of call between Eurofins Investor Relations and an investor"

"Cost of goods sold consists primarily of the cost of oats and other raw materials, product packaging, co-manufacturing fees, direct labor and associated overhead costs and property, plant and equipment depreciation. Our cost of goods sold also includes warehousing and transportation of inventory. Selling, general and administrative expenses include primarily personnel related expenses, brand awareness and advertising costs, costs associated with consumer promotions, product samples and sales aids. These also include outbound shipping and handling costs and other functional related selling and marketing expenses, depreciation and amortization expense on non-manufacturing assets and other miscellaneous operating items. — Prospectus"

"Sure. Their largest customer is Google. They don't disclose that for some reason. Maybe Google doesn't want to, but they do work with Google in Brazil, which is your largest customer, and in Chile as well as, and in Colombia, I guess, which is a very... because Dlocal their core business is doing cross-border payments, right? So, collecting locally, doing the exchange in remitting the money abroad. It's their core business where they make more money because you have this portion of doing the FX, right, converting on from local currency to U.S. dollars. And for Google they don't that, they do local collecting in local settlements. So, their margins there are very, very thin. But the volume of Google is just huge, right? — Source A"

"I cannot stand working with them...it feels like I’m talking to a used car salesman...they declined a heart transplant for one of our patients in the ICU because of this credit hold. I had to spend probably eight hours of my week on the phone with their rep, trying to beg and plead with them to release the hold because we didn't want to miss an opportunity to get an organ for one of our patients. I was groveling. The whole thing was a terrible experience. ... It was their COO, Tamer Khayal, who is not a clinician, who is the person that I find the most challenging to work with, like a used car salesman. ... He was part of this whole week where I was scrambling - he was part of the people threatening us. — Transplant administrator"

"“And the key to that was if it was cataplexy, you could get it covered...so, the trick was to get it covered under cataplexy because then you can reasonably get the $25 copay. Now, we market it for—I don’t know what we said…” — Ex-Harmony territory manager for a large region in the southeast across two states; “Then you get into a game as a rep of cataplexy, and you're really symptoms of cataplexy. Well, you ask the physician; yeah, I don't see cataplexy very much. And then you're like, Oh, yeah, doctor, you don't see their hand shaking or their eye quivering—and you're really stretching it because cataplexy gets covered on most insurance plans.” — Ex-Harmony territory manager for a large region in the southeast across two states"

"“Quinn, this is Michael. Although the company's strategy is that we don't really care in which market segment how we time it and how we time it in related to growing our MPS revenues, so these -- we actually -- in opposite, we don't want to -- we want to get associated with -- are we tied to Xbox, we tied to whatever the game console have, like game platforms, and the Intel, when they're going to release the -- into production of whatever the processor is. These are just our opportunity and that we only want to ensure our gross margin and a steady growth. And our customers phasing whatever the -- whichever the product is, we don't count that. And it's all within a plus/minus 6, 7 months, as I said earlier.” — CEO Hsing (Q1 2017)"

""Great union relationships are founded on really making the investment of ensuring that issues are brought in a timely fashion and dealt with." — Unknown Participant; "Having spent ten years of my life at the Southwest of Canada, and having been a part of some exciting changes that led to great outcomes, [it's exciting to have] the opportunity to be part of the grandfather of the low cost carriers, to help them get back to a point of real prominence and profitability in the industry." — Unknown Participant; "Southwest just has such a great story and such a great history and so many good things to be proud of and to leverage, that being a part of that, as an airline person, would be the best thing possible." — Unknown Participant"

"“Time Warner’s advanced broadband delivery systems are expected to provide an important distribution platform for America Online’s interactive services, which is expected to result in incremental subscriber growth.” — Company filings. “AOL is positioned and likely to become the leading provider of broadband Internet access.” — FTC Docket No. C-3989 (2000). “increase AOL/TWX’s ability to exercise unilateral market power.” — FTC Docket No. C-3989 (2000). “partnerships with other high-speed providers like DSL were made more difficult because people assumed AOL was in the cable camp. So instead of accelerating AOL’s broadband push, [the Merger] slowed it.” — Steve Case, It’s Time to Take it Apart, Washington Post, December 11, 2005."

"It's a very unique situation in the PWS community because Miller is a destination for these families... there's other interventions that are not evidence-based that she promotes, CoQ10, levocarnitine, MCT oil...she promotes these things as really important...and so, patients will go see her, and come back and want to start these non-evidence-based supplements...she's a proponent of these loosely evidence-based interventions for Prader-Willi Syndrome...and I feel like patients come back with a lot of requests, oftentimes, that are a little bit maybe out there that they're asking me to co-sign.... — Pediatric endocrinologist, leads one of the largest PWS clinics in US with 30-40 patients; 11 endocrinologists, major academic center"

"“I'm more concerned about the edema than the hyperglycemia...it's easier to monitor for the hyperglycemia than for the edema...that's been a question I've asked them: how do they clinically evaluate for edema if you're not going to be seeing the patient all the time?...I think 30% of drug patients, treated patients actually developed edema... I'm more worried about the edema”; “I personally am doing baseline cardiac evaluations on these patients...in case they do develop edema, which can put strain on the cardiac function... the proof is going to be when we start treating these patients and seeing what happens...we just have to wait and see what happens.” — Division Chief for pediatric endocrinology at a major NE academic center"

"Franchise Recruiter: A lot of the [prospects] would always have that concern, “Don’t you have an entire team focused on the DSW-Texas Area?” And what we were trained to say is that “You have the entire state of Texas,” and you have so many people in the state of Texas that there is enough to go around for everyone, is what they would tell you to say. Interviewer: That makes no sense... Franchise Recruiter: Yeah, no. It doesn’t. If you think about it. Interviewer: Yeah, because they are telling you to go face-to-face with somebody to develop a relationship, and I don’t know how you are going to do that from Dallas to San Antonio. Franchise Recruiter: Yeah, exactly. And it is a lot harder on the phone. — Former Franchise Recruiter"

"“There was no one in the battery R&D community that did not think that Sakti 3 was a fraud and was not angered by it. Everyone knew. GM invested, and I think, thanks to Khosla, found a greater fool in Dyson to dump it on. They had very, very small cells. They never really showed any performance data. It seemed to be a manufacturing process that would be expensive or impossible to scale up, and it never scaled.” — Solid-state expert; “Sastry’s peers in the battery industry were intensely skeptical...Among their questions: How many battery layers had Sakti3 stacked? (If it was a single layer, the claim was hardly worth reporting because it would lack a crucial feature known as specific energy density.)” — Quartz article 8/21/2015"

"“We are downgrading our rating on Alcoa to Neutral from Overweight as we believe the market will be disappointed with both the strategic direction from the new CEO, [Dr.] Klaus Kleinfeld, and the company’s near term earnings due to higher than expected input costs.” — J.P. Morgan, 6/10/08; “Throughout his speech, [Dr.] Kleinfeld kept emphasizing that Alcoa’s integrated structure is a key strength, not just for Alcoa but for the industry as a whole.” — Platts Metals Week Article, 9/15/08; “The Alcoa advantage raises the question that I have heard from many of you and I think that we more and more often have good answers to it raises the question of what gives you Alcoa the right to own that business?” — Dr. Kleinfeld, 11/10/2010"

""Our lease financing team inside SunPower has been very actively working on improving our lease offering as well. We're just a few days away from announcing a significant addition to our lease portfolio, which takes funding well through 2021. Most importantly, it doesn't just provide great lease capability to customers and our dealer partners, this technology actually increased our gross margins over $0.40 a watt. I would say this is one of the areas since we became much more focused on the space that has really improved our fundamental financials as a company. Advances in financing are playing a big part in driving our increased profitability, but also our increased dealer loyalty." — SunPower Investor Call, September 10, 2020"

""There have been assays that just flat out didn't work, and we had to reload and complete, and we really weren't able to necessarily pinpoint the source of the error." — Gilead scientist; "It would be the standard assay, so that's the fluorescent antibody expression technology that they have... it wasn't across every single colony or every single well or NanoPen, but it was enough that confounded the algorithm." — Gilead scientist; "I can't ferret out whether it's reagent, if it's cells, or if it's the specific antibody. I know it happens." — Gilead scientist; "Every run has some little twist and that's why I said you have to have somebody that is the product owner on the staff who knows how the thing works." — Gilead scientist"

"“I heard Waleed’s head almost exploded” — Prominent surgeon, Director of leading academic transplant center. “Whether I use TransMedics or whether I put it in a cooler of ice, I still get $300,000. But when I put it in the cooler of ice and bring the organ, my margin on the case is, let’s say, $100,000-120,000 or something. When I do it, and I then use the OCS device, my margin on the case is $10,000” — Transplant surgeon and transplant program director at a leading Northeast academic center. “All of this is very true and it very much eats up your margin...you are eating up a very, very substantial amount of the margin, no doubt about it.” — Transplant hepatologist and director of the liver program at a Midwest academic center."

"The biggest challenge is they have contracts with existing payment providers and the contracts can be two, three, four years. They won't change until that contract expires because there are penalties they would have to pay. The other, is it a business Lightspeed can support? When I was there, there were businesses that we could not underwrite. CBD was a big one we could not onboard. Then there is the competition with the actual payment providers. Since they are responsible for defining the pricing strategy, they can undercut Lightspeed in a second if they really care about the customer. Lightspeed does not have that negotiation power. They are restricted by the deal they have with their payment processor. — Former LSPD Employee"

""we're in discussions with Fidelity about doing maybe an extension with the lease, where it can be a lot more marketable and a lot more valuable to us on a sale basis." — Albright (Q4 2023 earnings call); "But to answer your question, we're waiting to find out how Fidelity wants to utilize it for the long term. And we're just kind of waiting on them..." — CTO Management (Q3 2024); "They came in on Wednesday, told us we had jobs, then turned around on Friday and fired us...it was disappointing. They said they were ‘going in a different direction,’ but they never explained why." — Ashley Collins; "This was a 70-hour-a-week job that required constant presence...how do you expect to replicate that from a distance?" — Ashley Collins"

"With respect to the Restructuring line item in particular, the Company believes its exclusion from the Company's calculation of Adjusted Gross Profit and Adjusted EBITDA is appropriate and not misleading because (i) it adjusts for expense items that are unusual, non-recurring, and in some cases non-cash operating expenses, (ii) the expenses reflected in the Restructuring line item have not been incurred at scale in the past and are not reasonably expected to be incurred at scale in the next two years and thereafter and (iii) the expenses reflected in the Restructuring line item are separate and distinct from the normal recurring cash expenses the Company expects to incur as a public company. — SEC Correspondence, April 6, 2021"

""The principal considerations for our determination that performing procedures relating to the cooperative marketing program accruals is a critical audit matter are (i) there was significant judgment by management to estimate the cooperative marketing program accruals, which in turn led to a high degree of auditor judgment in performing procedures to evaluate the status of trade promotion activities within the cooperative marketing program accruals, and (ii) there was a high level of audit effort and subjectivity in performing procedures to evaluate the current and past trade promotion spending patterns and the status of trade promotion activities used to determine the cooperative marketing program accruals." — Company filings"

"In November, we rolled out a trial plan, whereby the qualified agencies are provided with a different level of additional cash incentives if they reach certain growth targets. Although such incentives will likely cause cost in revenue to continue to fluctuate in the future, we believe it will better motivate the agencies and individual broadcasters to invest and grow their business within our ecosystem, which in turn will grow ours. — CFO Johnathan Zhang Q4 2017 Earnings Call; We scaled back the revenue oriented operating efforts around the quarterly competition event. Therefore, cost on bonus or rewards offered to broadcasters during the tournament, was significantly reduced. — Momo CFO Jonathan Zhang on Q1 2018 Earnings Call"

"I don't get it because Nevro's device is a piece of crap. I think people are picking up on it... The company couldn't care less about explant rates. They know. It's obvious. They don't want to hear from doctors because they already know this stuff. They've made a conscious decision. They don't give a shit. They just want to sell the company. — High volume implanter and KOL; Nevro keeps explant rates very well hidden from the field reps... The explant rate was a hell of a lot higher than [the stated] 2%. I don't know that people asked for it, because ignorance is bliss. I didn't want to know. Don't ask questions you don't want to know the answer to. My peers in the field felt the same way. — Former Nevro regional sales director"

""And then when high NA EUV comes, you can really shrink the pitch. That's why KLA says that for 5-nanometer, 3-nanometer, 2-nanometer, we think our optical inspection 193 system, along with 8xx multi-beam reticle inspection system is sufficient. And when high NA EUV comes with severe pitch reduction and mass pelliclization, you can bring in an actinic inspection system. We could have developed that earlier, but the complexity of the actinic system is much higher, and that's why we chose this path. And therefore, we are confident that we are ready for the market at the right time. And we're giving actinic the appropriate time to do the development and be ready whenever high NA EUV will be available." — Ahmad Khan, KLA executive"

"“All of the engineering and that synthetic biology happens in Boston. So, there’s that. I do think that was a bit of a power move…” — Former director-level employee; “Joyn was sort of set up as a, I mean, it was the first big joint venture, and it was set up to be independent. At the time, Ginkgo HR facilitated things, and there was some outsourcing of those types of G&A functions to Ginkgo, like they had kind of a part-time CFO, kind of independent contractor types that worked in different administration and executive functions. So, it wasn’t entirely run by Ginkgo, but it did leverage some kind of Ginkgo’s people in those roles, and it did use the same software systems and things like that.” — Former director-level employee"

"Whether the probability of winning or losing the game under the same gameplay of PLTK is within the reporting period is consistently, does PLTK adjust the probability of winning and losing irregularly or regularly; if so, supplementary disclosure of the frequency of adjusting the probability of winning and losing for different games during the reporting period and the winning and losing after each adjustment of the probabilities; whether or not there is a chance that PLTK will be able to fix the hand regardless of whether the player wins or loses. The situation in which a certain percentage of gold coins are obtained in the pool; and in each game, the total bet and the bet. Whether there is a cap on the number of bets. — CSRC"

""I think the biggest issue Dropbox faces as far as its growth story is concerned is the saturation. If you think about the amount of “knowledge workers” that are out there globally, and these are people who would want to register for Dropbox, it’s probably 500 – 600 million. But of this amount, maybe 50% would even consider purchasing something from Dropbox. Thus, Dropbox is pretty close to, if not already, close to the saturation point in terms of registered users growth." — Former Dropbox Leader (paraphrased); "We see ourselves as already having reached or registered a meaningful portion of the knowledge workers or our target audience, or knowledge workers on the planet, really." — CEO Drew Houston, Q1 2018 Conference Call"

"“A common question for new employees joining XL is, ‘why couldn’t the OEMs do it themselves?’ And the answer is it’s a small enough market that the amount of resources they’d have to deploy would be too large relative to the payoff. This runs contrary to the $1.4 billion in [projected] sales, which is significant enough that OEMs would love that incremental revenue… You would either have to acquire a lot of customers to get there or get existing customers to pay more. But there’s no way to get all these universities and cities to pay more than they are. And it’s very difficult to get a Fortune 500 company to get in on XL when you could go all in on a Tesla, a Rivian, something that’s much more proven.” — Former XL Employee D"

"“the downside...is hyperglycemia and maybe some of the peripheral edema, fluid retention, maybe exacerbating some heart failure”; “doesn't take much to make them diabetic...no surprise, given this mechanism of action...no surprise...and importantly, some patients get ketoacidotic because the insulin suppression is so potent at these doses that you essentially render the patient to be type-one diabetic...which could be potentially lethal in wide use”; “probably 40% of my patients with Prader-Willi, even at this young age, already have diabetes...I'll be especially leery about introducing diazoxide into a diabetic patient...important limitation on the overall kind of access to an already rare disease.” — PWS endocrinologist #1"

"I would say that many of my patients are on Facebook groups and so on...they've been excited for it...they've been wanting to start it as soon as it was released...but people positioned like me are probably prescribing it, but with some question about how successful it's going to be — Endocrinologist #6. The failure of the clinical trial and then the extension that had the signal, of course, I'm familiar with that...I agree that it's marginal...there is definitely some pressure and expectation from families — Endocrinologist #6. It's a very unique situation in the PWS community because Miller is a destination for these families... there's other interventions that are not evidence-based that she promotes — Endocrinologist #6."

"a lot of people here wouldn't— wouldn't touch him, wouldn't go near him because getting four years in Israel back then is like getting, you know, 14 years today... and that conviction... maybe because of other things, he cannot go to the US. It was kind of weird. I mean, we were meeting banks and he was like in the other room because they wouldn't, you know... he was doing the whole thing. And then the Israelis that knew who he was, he would not come to the company at that day because they knew who he was. Yeah, so he's the guy, real guy behind it... they [A-Labs] would do work. I imagine in terms of crafting the narrative and the pitch book and so forth. And I mean, basically, promoting the valuation. — Former NNOX employee"

""When I order something on phase two/phase three because of these big quantities, they are also really big orders that may be one oligo where one lot is $50,000. But then we will use that lot for the next probably six to nine months. And then something that may be interesting that they could also offer is that because when we order these very big lot, for us, it's very important that everything is from the same lot because when you work on the GMP, every time that you change the lot, you need to qualify it. If we had to qualify every kind of two months, it doesn't make sense because people in the lab lose time, and this means money and time for the company." — Novartis, a large Twist customer, scientist in a leadership role"

"Subsequent to the closing of the transaction, during the second quarter of 2023 Mr. Watsa, to avoid potential future conflicts of interest, sold all of his 678,021 shares of Poseidon to Fairfax. Mr. Watsa owned 678,021 shares of Atlas representing less than 0.3% ownership as an investment that were replaced with shares of Poseidon on a one-for-one basis as a result of the tender offer as part of the consortium described above. Mr. Watsa sold the Poseidon shares to Fairfax at $15.50 per share, the same price he could have obtained under the tender offer and the price at which Fairfax's shares of Atlas were valued by the consortium which made the tender offer. — Fairfax Financial Holdings Financial Statements Q2 2023, Pg. 22."

"“Our technology is complex, and we struggled to find a government consultant who could understand it well enough to be effective without us having to do all the work. Clark Street’s approach—combining deep technical, business, and government expertise in multidisciplinary teams—allowed them to get up to speed fast and bring real strategic insight without us needing to be in every meeting. They were able to craft and communicate a compelling strategy on our behalf, positioning us for substantial funding that has been transformative. Clark Street’s ability to understand and advocate for our technology independently, without our constant oversight, is exactly what we were looking for in a partner.” — Peter Chapman, CEO of IonQ"

"“Due to staffing shortages and other logistics challenges at IDTFs, results reporting can take many days, weeks, or even more than a month before physicians receive patient results. Diagnostic delays, patient data breaches and fragmented care are often the undesired effects of outsourcing ECG services. Thanks to recent innovations in automated ECG analysis algorithm technology, providers can now bring long-term ECG patch data analysis and draft reporting entirely in-house, streamlining the process and reducing overall time to patient diagnosis. ‘Insourcing’ rather than outsourcing ECG services can also reduce operational costs and maximize reimbursement for providers.” — Diagnostic and Interventional Cardiology (DAIC) Blog"

""Our guidance reflects the Company's current view of the business," said Jay Rembolt, WD-40 Company's vice president and chief financial officer. "The revenue softness we experienced in the first quarter was primarily driven by the timing of customer orders and we expect that sales activity will shift into later quarters. We remain comfortable with our current guidance range and are reiterating it today." — Jay Rembolt; "Though these results may look disappointing, they no way reflect a trend. In fact, we see lots of opportunities for growth as we continue to maximize the product line through geographic expansion, increased market penetration and premiumization of the blue and yellow can with a little red top". — CEO Ridge"

""All the things about diabetes and the blood sugar risk, they're going to basically prescribe the medication with a glucometer. They're going to actually — I think they're going to have a process where the glucometer gets sent to the family with the medication. And using one medication to treat the other —. I saw lots of babies that were put on diazoxide, and the dose was too high, and they had hyperglycemia, so, we decreased it. But there's not really a good — in the babies with hyperinsulinism, we're adjusting it because of hyperinsulinism. And these guys, they're at risk for diabetes or they might be pre-diabetic." — Pediatric endocrinologist at a Delaware academic center with eight endocrinologists and ~50 PWS patients"

"“All the things about diabetes and the blood sugar risk, they’re going to basically prescribe the medication with a glucometer. They’re going to actually — I think they’re going to have a process where the glucometer gets sent to the family with the medication. And using one medication to treat the other —. I saw lots of babies that were put on diazoxide, and the dose was too high, and they had hyperglycemia, so, we decreased it. But there’s not really a good — in the babies with hyperinsulinism, we’re adjusting it because of hyperinsulinism. And these guys, they’re at risk for diabetes or they might be pre-diabetic.” — Pediatric endocrinologist at a Delaware academic center with eight endocrinologists and ~50 PWS patients"

"When I was at HIMS, the vast majority, if not all of us, had a day job, and HIMS was just there to supplement our income. Some were like hospitalists where they worked seven days on, seven days off, and then during those seven days off they'd log into the system. Others were like working urgent care shifts or overnight shifts. They wouldn't see a patient for two hours, so they sit down and log on and just chip away at some of the charts. I don't recall anybody being dedicated to telemedicine. Nobody goes to medical school to be a telemedicine doctor. It was fairly common to sign a doctor up, they work for a couple weeks, and then they're never seen again on the platform. — Spruce Point Interview With Former HIMS Physician"

""It is our intention within the 24-month period to be able to take this combined business, this pigments business, which will be in excess of $3.5 billion in sales..." — Peter Huntsman, President & CEO, September 2013; "It is our intention within the 24-month period to be able to take this combined business, this pigments business... and have a normalized EBITDA in excess of $0.5 billion" — Peter Huntsman, President & CEO, September 2013; "We continue to remain focused as a Company and our Board of Directors on deleveraging. I think that when you look at our targets going out 2015 and 2016...our leverage ratios go to our long-time stated objective of 2.0 times our EBITDA." — Peter Huntsman, President & CEO, September 2013"

""When we receive export incentives in Nigeria which are recorded separately as a line item in our P&L, we have to pass on almost all of this to our suppliers thereby increasing our costs of procurement. Therefore, what is recorded as export incentives does not directly flow down to our profits." — Olam, "Clarifications on CSLA Analyst Report dated 21st February 2011". "The Export Expansion Grant is an initiative of the Federal Government, aimed at encouraging exporters of non-oil products..." — http://allafrica.com/stories/201208290128.html. "The EEG is not under any threat... We are putting structures in place to make sure that the EEG is not abused in the future." — Nigerian Minister of Trade and Investment, Mr. Aganga."

"Triller did a last private round of capital raising just about 12-13 months ago, valuing it at over $3B — Ng. Our contribution is scaling the business. And we have a specific plan how to make money. It requires a few things. #1 people, and #2 capital. I'm fortunate to say at this moment, that we have a lot of capital chasing us. And #3 ideas. — Ng. Agba's financial expertise and Triller's AI-driven capabilities are incredibly complimentary. At the core of a social media company and the core of a financial services company, is really recommendations. — Ng. As a part of this merger, the entire company will be redomiciled, relocated to Los Angeles. We have a team going around in Los Angeles looking for a campus for us. — Ng."

"Moving to our guidance for the first quarter of 2018. We expect revenues to be in the range of $28 million to $31 million. We expect non-GAAP adjusted operating income to be in the range of minus 2% of revenues to 3% of revenues. These numbers assume no impact of deferred value of issued warrants in the first quarter of 2018. The calculation of warrants per value is based on the combined effect of estimation of future revenues from Amazon, future Kornit share price in an unknown date, Kornit future stock volatility as well as other variables that currently cannot be predicted. Since we are not able to predict these variables, we'll assume the warrants impact at 0 value for guidance purposes. — CFO on Q4'17 Investor Call"

"“Pretty quiet.” — Nephrologist who manages PWS patients; “I have not been visited by a drug rep or anyone like that. I do think that it's feast or famine. If we do have a patient, they want to get on it, I'm happy to help them, as long as it doesn't become labor-intensive. But sometimes, the pre-authorization process is labor-intensive, and you have to write a few letters and stuff. It takes a lot of time.” — Nephrologist who manages PWS patients; “I think it's going to be tough to justify it if you have a lot of volume. But I think the physicians will try it once or twice. And if they find out that they're not getting approved or there's too much work, they may try the generic.” — Nephrologist who manages PWS patients."

"“You can demonstrate the elementary functionality that a quantum computer enables. It allows you to run lab demonstrations of the kinds of computations that you would want to run eventually on scalable quantum computers. And it does not outperform any classical computer whatsoever. It’s too small and too noisy in order to be able to accomplish that. So, if you want to demonstrate a single quantum algorithm such as Bernstein-Vazirani or Grover’s Search over a small case, maybe 16 elements or some simple computation like that, then you would use the trapped ion device or the IonQ device. It’s for educational purposes; I would say, only.” — Leading quantum computing researcher who has published papers with IonQ’s founders"

"“Because of what we've done over the last 25 years, we have every single data point about the student. We understand their demographics, we understand siblings. We understand the bus routes. You may not believe what -- or think about what an impact a bus route can make on students' academic performance. But that's a really real factor. And that's the type of data that we have in our platform.” “We, of course, have all of their test scores, the courses that they've been taught, their grades, the attendance, the behavior incidents, programs, enrollments, teachers that are teaching them, what they're being taught in the class, how much of time do they spend online in our systems.” — 2023 PowerSchool Investor Day Statement"

"“Yes, it was changed because a new CFO came. He came with a lot of expertise. For all those years of Oatly, the finance and accounting function didn't grow with the Company and was behind. They needed to professionalize. He took over and made changes, probably restructured the finance and accounting department with more emphasis on costing. The prior CFO, Peter Bergh, became COO.” — Former Oatly Accounting Professional; “Fifteen months later, the dark days have brightened—for baristas, coffee lovers, and especially Oatly AB. In April, the Swedish company widely credited with creating the oat milk category opened a $15 million U.S. processing plant in Millville, N.J.—the first outside Europe.” — Bloomberg, July 31, 2019"